
Opinion|Videos|December 11, 2024
Case 2: Low-Volume Recurrent mCSPC
Panelists discuss how the management of low-volume recurrent metastatic castration-sensitive prostate cancer (mCSPC) focuses on personalized treatment strategies, including the use of androgen deprivation therapy and targeted therapies, to achieve optimal outcomes while minimizing treatment-related toxicity.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
AI-generated profiles impersonate female urologists to market ED products online
2
John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
5






